tradingkey.logo
tradingkey.logo
Buscar

ImmuCell Corp

ICCC
Añadir a la lista de seguimiento
10.290USD
-0.710-6.45%
Cierre 07/02, 13:00ETCotizaciones retrasadas 15 min
93.09MCap. mercado
PérdidaP/E TTM

Más Datos de ImmuCell Corp Compañía

ImmuCell Corporation is an animal health company. The Company is engaged in the development, acquisition, manufacture, and sale of products that improve the health and productivity of dairy and beef cattle. It operates in two business segments: Scours and Mastitis. The Scours segment is engaged in manufacturing and selling First Defense, a product used to prevent scours in newborn calves. The Mastitis segment includes products called California Mastitis Test and Re-Tain. Re-Tain, a novel treatment for subclinical mastitis in dairy cows, is in the late stages of development. The First Defense product line provides bovine antibodies that newborn calves need but are unable to produce on their own immediately after birth. Its product line extension, Tri-Shield First Defense, is the first calf-level, passive antibody product providing immediate immunity against each of the three causes of calf scours (E. Coli, coronavirus, and rotavirus).

Información de ImmuCell Corp

Símbolo de cotizaciónICCC
Nombre de la empresaImmuCell Corp
Fecha de salida a bolsaMay 01, 1987
Director ejecutivote Boekhorst (Olivier)
Número de empleados69
Tipo de seguridadOrdinary Share
Fin del año fiscalMay 01
Dirección56 Evergreen Drive
CiudadPORTLAND
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal04103
Teléfono12078782770
Sitio Webhttps://immucell.com/
Símbolo de cotizaciónICCC
Fecha de salida a bolsaMay 01, 1987
Director ejecutivote Boekhorst (Olivier)

Ejecutivos de ImmuCell Corp

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Michael F. Brigham
Mr. Michael F. Brigham
Director
Director
216.70K
--
Dr. David Scott Tomsche, M.D.
Dr. David Scott Tomsche, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
131.39K
-1.55%
Ms. Bobbi Jo Brockmann
Ms. Bobbi Jo Brockmann
Vice President - Sales and Marketing, Director
Vice President - Sales and Marketing, Director
8.52K
--
Mr. Bryan K. Gathagan
Mr. Bryan K. Gathagan
Independent Director
Independent Director
1.00K
--
Mr. Paul R. Wainman
Mr. Paul R. Wainman
Independent Director
Independent Director
--
--
Mr. Steven T. Rosgen
Mr. Steven T. Rosgen
Independent Director
Independent Director
--
--
Ms. Gloria J. Basse
Ms. Gloria J. Basse
Independent Director
Independent Director
--
--
Mr. Timothy C. Fiori
Mr. Timothy C. Fiori
Chief Financial Officer, Treasurer, Secretary, Director
Chief Financial Officer, Treasurer, Secretary, Director
--
--
Mr. Olivier te Boekhorst
Mr. Olivier te Boekhorst
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Michael F. Brigham
Mr. Michael F. Brigham
Director
Director
216.70K
--
Dr. David Scott Tomsche, M.D.
Dr. David Scott Tomsche, M.D.
Independent Non-Executive Chairman of the Board
Independent Non-Executive Chairman of the Board
131.39K
-1.55%
Ms. Bobbi Jo Brockmann
Ms. Bobbi Jo Brockmann
Vice President - Sales and Marketing, Director
Vice President - Sales and Marketing, Director
8.52K
--
Mr. Bryan K. Gathagan
Mr. Bryan K. Gathagan
Independent Director
Independent Director
1.00K
--
Mr. Paul R. Wainman
Mr. Paul R. Wainman
Independent Director
Independent Director
--
--
Mr. Steven T. Rosgen
Mr. Steven T. Rosgen
Independent Director
Independent Director
--
--

Preguntas frecuentes

¿Quiénes son los cinco principales accionistas de ImmuCell Corp?

Los cinco principales accionistas de ImmuCell Corp son: Mr. Michael F. Brigham

¿Cuántas instituciones poseen acciones de ImmuCell Corp (ICCC)?

A fecha de 2026Q1, 48 instituciones poseen acciones de ImmuCell Corp, con un valor de mercado combinado de aproximadamente 2.16M, lo que representa el 23.86% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en 228934.00.

¿Cuál es la mayor fuente de ganancias de ImmuCell Corp?

El 2026Q1, el segmento empresarial First Defense® product line generó la ganancia más alta para ImmuCell Corp, ascendiendo a 27.45M y representando el 99.29% de la ganancia total.